While some therapeutic approaches use the CNTF or control subretinal neovascularization with the anti-vascular endothelial growth factor (VEGF) therapies—commonly used in conditions like diabetic retinopathy [69] and age-related macular degeneration [70]—the results from these strategies fall short of providing a truly effective solution. The gene discussed is VEGFA; the disease is diabetic retinopathy.